• Role of antimicrobials

    Scaling and root planning (SRP) is the gold standard regimen for periodontal disease. However, pharmacological treatment can help eliminate pathogens in deep pockets or furcations, where mechanical treatment may have been less efficient. Matesanz (2013) reported that “the subgingival application of an antimicrobial adjunctively to SRP demonstrated additional clinical benefits (especially in PPD reductions).“ (1)

    Importance of sustained contact

    According to Matesanz, “ it is important not only to select the therapeutic agent, but the resulting pharmacokinetic profile, mainly due to the vehicle utilized for its topical application” Moreover, “scientific evidence supports the adjunctive use of local antimicrobials to SRP in deep or recurrent periodontal sites, mostly when the vehicle has shown pharmacodynamic properties assuring the sustained release of the antimicrobial.”

    GUIDOR® Periocline (minocycline 2 %) with its special slow-release microsphere process used as an adjunct to mechanical debridement, ideally matches the requirements described.


    1. Matesanz-Pérez P1, García-Gargallo M, Figuero E, Bascones-Martínez A, Sanz M, Herrera D., A systematic review on the effects of local antimicrobials as adjuncts to subgingival debridement, compared with subgingival debridement alone, in the treatment of chronic periodontitis, J Clin Periodontol. 2013 Mar; 40(3): 227-41.

  • Active ingredient: minocycline

    GUIDOR® Periocline contains the active ingredient minocycline at a concentration of 2%. Minocycline is one of a group of antibiotics called tetracyclines.


    Localized action:

    • With targetted antimicrobial efficiency on (1,2):
        • Anaerobes: Porphyromonas gingivalis, Prevotella intermedia, Tannerella forsythia, Eikenella corrodens, Aggregatibacter actinomycetemcomitans
        • Spirochetes: Treponema denticola
    • High concentrations in-situ, low systemic concentrations (3)
        • In a pharmacokinetic study, concentrations of minocycline in gingival crevicular fluid remained at clinical-effective levels for a minimum of three days following the administration of 0.05 g of gel (1 mg minocycline) into periodontal pockets.
        • Serum levels after subgingival administration and even after direct oral administration of 0.5 g of gel (10 mg minocycline) were only in the range of 0.1-0.2 µg/ml. These levels are much lower than the serum levels which would be associated with the normal oral dose of 100-200 mg/day minocycline used in systemic therapy.


    Eudragit® process:

        • Periocline is a light yellow-coloured ointment. The exclusive process of micro encapsulation (Eudragit®) allows continuous, regular and slow release of the minocycline drug over several days.
        • Thanks to the specific technology of our Eudragit Process, the active ingredient minocycline hydrochloride is gradually released in situ from the microsphere formulation after application of the gel into the periodontal pocket. Moreover, minocycline has a high affinity for the surfaces of the tooth and therefore remains available in situ after release from the formulation. Therefore, GUIDOR®Periocline provides a simple-to-apply, sustained release adjunctive treatment for periodontitis.



    1. Satomi et al. Minocycline HCl concentration in periodontal pocket after administration of LS007. Journal of Japanese Society of Periodontology, 1987; 29(3) : 937-43

    2. Mc Coll E, Patel K, Dahlen G, Tonetti M, Graziani F, Suvan J, Laurell L. Supportive periodontal therapy using mechanical instrumentation or 2 % minocycline gel : a 12 month randomized controlled, single masked pilot study. J Clin Periodontol. 2006 ; 33 : 141-50

    3. SmPC

  • Easy to handle: single-use prefilled syringe with atraumatic canula.

    GUIDOR® Periocline is intended to be applied directly into the periodontal pocket by means of the specially designed applicator.

    GUIDOR® Periocline should be administered following scaling and root planning, to periodontal pockets with probing depth of at least 5mm. The tip of the applicator should be inserted to the point of resistance in each pocket to be treated before the medication is administered. The amount of Periocline administered should be sufficient to fill each pocket to the point of overflow. Tooth brushing, flossing, mouth washing or eating should be avoided for at least 2 hours immediately following administration of the medication.


    Local product name*:

    France: Parocline

    Greece: Periocline

    Japan/China/South Korea/Taiwan: Periocline

    *Note: product characteristics and Patient Information Leaflets (PIL) are country dependent. Please check with your local contact and read local PIL carefully before use.
  • Local antibiotic as an adjunct to scaling and root planning (SRP) procedures in the treatment of periodontal diseases in periodontal pockets >5mm


    1 box = 3 syringes = 1 patient
    To be stored in the refrigerator

    SmPC/ Contra-indications

    Put SmPC with all the adverse effects, contra-indications (allergies), precautions (pregnant or lactating women, children under 8 or 12, renal diseases…)

Back to top